{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:47:18Z","timestamp":1774961238662,"version":"3.50.1"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-performance blood tests may improve diagnostic accuracy and support personalized treatment for Alzheimer's disease (AD), but validation at the time of initial clinical diagnosis remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess whether plasma biomarkers can aid diagnostic decision-making at first clinical assessment, particularly as tools to triage patients for confirmatory testing in routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed 241 cognitively normal (CN) controls, 211 patients with mild cognitive impairment (MCI), and 59 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. Plasma aliquots underwent analysis with the C2N Diagnostics PrecivityAD2\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and Roche Diagnostics Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The AD group showed a lower A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      ratio than the CN group (p\u2009&lt;\u20090.01) and a mild decrease compared to the MCI group (p\u2009&lt;\u20090.05). The AD group had significant increases in p-tau181, p-tau217, and %p-tau217 (p\u2009&lt;\u20090.001) versus both MCI and CN groups. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were also significantly elevated in AD. The MCI and CN groups only differed in p-tau217 and %p-tau217 (p\u2009&lt;\u20090.05). The AD versus CN AUCs for p-tau181, p-tau217, and %p-tau217 were 0.84, 0.87, and 0.87; for AD versus MCI, they were 0.79, 0.80, and 0.81. The p-tau181, p-tau217, and %p-tau217 showed a moderate correlation with the Alzheimer's Disease Assessment Scale-cognitive subscale. %p-tau217 demonstrated a strong correlation with the p-tau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio in CSF (R\u2009=\u20090.72, p\u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the setting of first-presentation diagnosis of clinically defined MCI and AD, p-tau217, and %p-tau217 outperformed other plasma biomarkers and may help triage patients for further confirmatory evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823261439687","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:47:18Z","timestamp":1774957638000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["P-tau217 and %p-tau217 exhibited superior diagnostic accuracy over other blood biomarkers in the initial assessment of individuals being diagnosed with mild cognitive impairment and Alzheimer's disease dementia"],"prefix":"10.1177","volume":"10","author":[{"given":"Qiongqiong","family":"Qiu","sequence":"first","affiliation":[{"name":"Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Qian","sequence":"additional","affiliation":[{"name":"Xiaohe Health-Medical Operation, Beijing Zitiao Network Technology Co., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Xuanwu Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxin","family":"Xie","sequence":"additional","affiliation":[{"name":"Beijing Rehabilitation Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Xuanwu Hospital, Capital Medical University"},{"name":"Department of Rehabilitation, Xiong'an Xuanwu Hospital, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-8989","authenticated-orcid":false,"given":"Linlin","family":"Ye","sequence":"additional","affiliation":[{"name":"Xuanwu Hospital, Capital Medical University"},{"name":"Department of Rehabilitation, Jinan Hospital of Xuanwu Hospital, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13764"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12283"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13862"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad267"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333"},{"key":"e_1_3_3_11_2","unstructured":"Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's disease neuroimaging protocol (ADNI). Report Laboratory of Neuro Imaging University of California Los Angeles CA 2005."},{"key":"e_1_3_3_12_2","unstructured":"Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core. Methods & tools\/research methods\/biomarker analysis\/biofluid banking. Report University of Pennsylvania Philadelphia PA 2024."},{"key":"e_1_3_3_13_2","unstructured":"Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI3 biomarker biofluid collection processing and shipment. Report UPENN Biomarker Laboratory\/Alzheimer's Therapeutic Research Institute 2017."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.09.009"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.220392"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.06.1513"},{"key":"e_1_3_3_17_2","first-page":"746","article-title":"Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database","volume":"67","author":"O'Bryant SE","year":"2010","unstructured":"O'Bryant SE, Lacritz LH, Hall J, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 2010; 67: 746\u2013749.","journal-title":"Arch Neurol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00451-6"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.05.011"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.06.2266"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00214-3"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12706"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3180"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12787"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000306696.82017.66"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170458"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1359"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.06.001"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"key":"e_1_3_3_33_2","article-title":"Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: the Shanghai aging study","volume":"15","author":"Xiao Z","year":"2023","unstructured":"Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: the Shanghai aging study. Alzheimers Dement (Amst) 2023; 15: e12514.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.2293"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-230029"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.6117"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001642"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.05.018"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0304-3"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12447"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666201223154009"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3671"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae396"},{"key":"e_1_3_3_45_2","first-page":"6668159","article-title":"Novel biomarkers for Alzheimer's disease: plasma neurofilament light and cerebrospinal fluid","volume":"2024","author":"Abukuri DN","year":"2024","unstructured":"Abukuri DN. Novel biomarkers for Alzheimer's disease: plasma neurofilament light and cerebrospinal fluid. Int J Alzheimers Dis 2024; 2024: 6668159.","journal-title":"Int J Alzheimers Dis"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535"},{"key":"e_1_3_3_48_2","article-title":"Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: real-world implementation, clinical utility, and diagnostic performance","volume":"21","author":"Araujo IPQC","year":"2025","unstructured":"Araujo IPQC, Ellingson T, Schwartz NU, et al. Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: real-world implementation, clinical utility, and diagnostic performance. Alzheimers Dement 2025; 21: e70891.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12640"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14242"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00333-6"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.3029"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261439687","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823261439687","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261439687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:47:21Z","timestamp":1774957641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823261439687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["10.1177\/25424823261439687"],"URL":"https:\/\/doi.org\/10.1177\/25424823261439687","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"25424823261439687"}}